News | January 08, 2026
Arrowhead Pharmaceuticals gets green light for first-of-its-kind FCS therapy
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Heart failure affects an estimated 64.3 million people worldwide
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
The approval introduces a needle-free alternative to injectable GLP-1 therapies
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Subscribe To Our Newsletter & Stay Updated
